Since the 2013 Supreme Court ruling on BRCA1/BRCA2 patenting, hereditary cancer 
gene panels now include BRCA1 and BRCA2, making these panels an option for 
first-tier testing. However, questions remain about the clinical utility and 
implications of these panels for medical management with inclusion of genes of 
unknown to moderate penetrance. To better understand how use of these panels 
affected our practice, we reviewed patients who underwent testing in our clinic 
from July 1, 2013 through May 23, 2014. Indications for testing included 
personal and/or family history of breast and/or ovarian cancer. A total of 136 
patients underwent panel testing via a single commercial laboratory; 12 (8.8 %) 
patients were positive for a pathogenic or likely pathogenic mutation (four 
BRCA2 mutations, two TP53 mutations, one CDH1 mutation, two ATM mutations, and 
one patient each with a CHEK2, NBN, or PALB2 mutation). Of these positive 
patients, 100 % met the National Comprehensive Cancer Network (NCCN) guidelines 
for Hereditary Breast and Ovarian Cancer genetic testing (2.2014). Mutations in 
seven of twelve (58 %) patients led to changes in medical management; three of 
seven (43 %) had a non-BRCA1 or BRCA2 gene mutation. Our findings suggest that 
there is clinical utility of panels that include genes of unknown to moderate 
penetrance.